Similarly, ramucirumab (anti-VEGFR2) plus NIVO (anti-PD-1) resulted in favorable clinical outcomes in non-epithelioid mesothelioma compared with historical data for NIVO monotherapy, with an acceptable safety profile and no grade ≥ 4 toxicities observed [122]. Here, KDR is linked to mesothelioma.